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Abstract
Background: Sodium tungstate is known to be an effective anti-diabetic agent, able to increase beta cell mass in animal models
of diabetes, although the molecular mechanisms of this treatment and the genes that control pancreas plasticity are yet to be
identified. Using a transcriptomics approach, the aim of the study is to unravel the molecular mechanisms which participate in
the recovery of exocrine and endocrine function of streptozotocin (STZ) diabetic rats treated with tungstate, determining the
hyperglycemia contribution and the direct effect of tungstate.
Results: Streptozotocin (STZ)-diabetic rats were treated orally with tungstate for five weeks. Treated (STZ)-diabetic rats
showed a partial recovery of exocrine and endocrine function, with lower glycemia, increased insulinemia and amylasemia, and
increased beta cell mass achieved by reducing beta cell apoptosis and raising beta cell proliferation. The microarray analysis of
the pancreases led to the identification of three groups of differentially expressed genes: genes altered due to diabetes, genes
restored by the treatment, and genes specifically induced by tungstate in the diabetic animals. The results were corroborated
by quantitative PCR. A detailed description of the pathways involved in the pancreatic effects of tungstate is provided in this
paper. Hyperglycemia contribution was studied in STZ-diabetic rats treated with phloridzin, and the direct effect of tungstate
was determined in INS-1E cells treated with tungstate or serum from untreated or treated STZ-rats, observing that tungstate
action in the pancreas takes places via hyperglycemia-independent pathways and via a combination of tungstate direct and
indirect (through the serum profile modification) effects. Finally, the MAPK pathway was evaluated, observing that it has a key
role in the tungstate-induced increase of beta cell proliferation as tungstate activates the mitogen-activated protein kinase
(MAPK) pathway directly by increasing p42/p44 phosphorylation and indirectly by decreasing the expression of raf kinase
inhibitor protein (Rkip), a negative modulator of the pathway.
Conclusion: In conclusion, tungstate improves pancreatic function through a combination of hyperglycemia-independent
pathways and through its own direct and indirect effects, whereas the MAPK pathway has a key role in the tungstate-induced
increase of beta cell proliferation.
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The endocrine pancreas is continually remodelled [1] in a
dynamic process involving the death and regeneration of
beta cells. Though several mechanisms have been impli-
cated in adult beta cell maintenance and renewal [2], it
has been demonstrated that the proliferation of differen-
tiated beta cells is the major mechanism for the mainte-
nance of adult beta cell mass [3]. Nevertheless, it has
recently been shown that endogenous progenitors can
participate in the increase in beta cell mass in adult mice
[4].
Studies in several animal models of diabetes have shown
sodium tungstate to be an effective anti-diabetic agent,
able to reverse hyperglycemia [5-9]. Tungstate treatment
normalizes liver glucose metabolism in streptozotocin
(STZ) and Zucker Diabetic Fatty (ZDF) rats [5,7],
improves beta cell function in neonatal streptozotocin
(nSTZ) rats [6], and also decreases hypertriglyceridemia in
ZDF-rats [7]. In nSTZ-rats, tungstate not only restores glu-
cose-induced insulin secretion, but also completely regen-
erates beta cell mass, leading to normoglycemia in
animals even after withdrawal of the treatment [9].
Sodium tungstate has also been shown to exert insulin-
mimetic effects in isolated hepatocytes [10] and to
increase insulin content and enhance insulin secretion in
the presence of glucose and various segretagogues in an
insulinoma cell line and the perfused pancreas [11,12].
The aim of this study is to unravel the molecular mecha-
nisms of tungstate action in the pancreas. Streptozotocin
is a diabetogenic compound and is known to specifically
destroy beta cells in the pancreas, obtaining a diabetic ani-
mal model with impaired endocrine and exocrine func-
tion and reduced beta cell mass. In this model, we
identified the pancreatic gene expression changes induced
by the streptozotocin damage and the partial recovery of
function after treatment with tungstate. The data pre-
sented here show that tungstate treatment modifies the
expression of a set of genes which participate in the tung-
state-induced pancreatic plasticity, with a recovery of exo-
crine function and a partial recovery of endocrine
function and beta cell mass. Moreover, we demonstrate
that most of these effects are independent of the recovery
of hyperglycemia and due to direct and indirect effects of
tungstate in the pancreas. Further study of these pathways
may lead to the discovery of new strategies for modifying
pancreatic plasticity.
Results
Effects of tungstate treatment on blood and beta cell 
parameters
As previously described [5,8], administration of sodium
tungstate significantly decreased glycemia in STZ-rats,
while no changes were observed in the healthy animals
(Figure 1a). Similarly, the administration of tungstate to
STZ-rats also increased beta cell mass, though without
reaching the levels found in the healthy animals (percent-
age of insulin area in the total pancreatic area, healthy
untreated [HU]: 1.77 ± 0.27, healthy treated [HT]: 1.82 ±
0.26, diabetic untreated [DU]: 0.05 ± 0.01 p < 0.01 vs. HU,
diabetic treated [DT]: 0.20 ± 0.05 p < 0.01 vs. both DU
and HU, n = 6). In agreement with previous reports [8],
tungstate treatment did not induce any significant modi-
fication in the healthy animals, and consequently, no fur-
ther morphological analysis of these animals was
performed. Figure 1b shows representative images of insu-
lin-immunostained pancreas. Moreover, tungstate treat-
ment in the diabetic animals also induced a significant
increase in the number of positive insulin and Pdx-1 cells
in the islets (Figures 1c and 1d). In order to understand
the mechanisms involved in the increase in beta cell mass,
we measured beta cell replication and apoptosis rates. As
shown in Figure 1e, the diabetic rats had a higher number
of apoptotic cells than the healthy animals. The treatment
significantly decreased the rate of beta cell apoptosis,
reaching levels comparable to those found in the healthy
animals (Figure 1e). Moreover, tungstate increased beta
cell replication in the diabetic animals (Figure 1f). These
increases in beta cell mass and function were accompa-
nied by a significant increase in blood insulin levels in the
diabetic treated animals (Figure 1g). Therefore, the
increased beta cell mass observed could be ascribed to a
combination of the recovery of the apoptotic levels and
the increased proliferation levels. This rise does not nor-
malize beta cell mass, probably due to the extremely low
levels of beta cell mass in the STZ-rats and the cells' lim-
ited capacity for recovery and replication. Nevertheless,
the stimulation of the treatment permits a four-fold
increase in beta cell mass and a two-fold increase in
insulinemia in the animals. Moreover, although strepto-
zotocin is a beta cell-specific toxin, it has also been
reported that STZ-rats have impaired exocrine function
[13], which was confirmed by the lower blood amylase
levels in the diabetic animals; these levels were also
improved by tungstate administration (Figure 1h).
Gene expression profile of diabetic treated animals
To understand the underlying molecular mechanisms of
tungstate action in the pancreas and to identify the tung-
state target genes, we used microarrays to determine the
gene expression in the four experimental groups. We per-
formed microarrays of the whole pancreas in order to
evaluate the possible signals coming from exocrine, ductal
and endocrine tissue which might explain the phenotype
observed. The differential expression analysis identified
370 differentially expressed genes, with clustered values
(Figure 2a). The heat diagram clearly shows that the genes
selected make it possible to distinguish between the
healthy and diabetic groups, and between the treated and
untreated diabetic samples. This distinction elegantly
mimics the glycemic phenotype observed: the glycemiaPage 2 of 13
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Effects of tungstate administration on blood and beta cell parametersFigure 1
Effects of tungstate administration on blood and beta cell parameters. a Glycemia evolution of healthy untreated 
(open circles), healthy treated (filled circles), diabetic untreated (blank squares) and diabetic treated (filled squares) rats, n = 9. 
b Representative images of pancreatic sections stained with insulin (magnification 20×) for HU, DU and DT.c, d The percent-
age of insulin (c) and Pdx-1 (d) positive cells in the islets was analyzed from the pancreas (at three different levels), n = 6. e, f 
Beta cell apoptosis (e) and proliferation (f) were assessed by propidium iodide and Pcna staining, respectively, n = 8–10. g, h 
Insulin (g) and amylase (h) serum levels at the end of the tungstate treatment, n = 8–10. ***p < 0.001 and **p < 0.01 compared 
to healthy untreated animals, †††p < 0.001, ††p < 0.01 and†p < 0.05 compared to diabetic untreated animals.
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Differential gene expression in the pancreas of the diabetic untreated and treated animalsFigu  2
Differential gene expression in the pancreas of the diabetic untreated and treated animals. a Clustering of all the 
genes differentially expressed (horizontally) and the samples from the different experimental groups (vertically) using the dChip 
software.b, c Functional classification of the genes differentially expressed in the pancreas of diabetic animals (b) and in the 
pancreas of diabetic treated animals (c). The analysis of the arrays and identification of the differentially expressed genes was 
performed as described in Additional file 9. The functional classification of the genes was performed with the help of the 
NetAffx and GeneOntology databases.
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untreated healthy animals, but not in the treated and
untreated diabetic animals. Moreover, the heat diagram
grouped these genes in three different clusters: genes mod-
ified by diabetes, genes whose expression was restored by
the treatment, and genes modified only in the diabetic
treated animals.
In Figure 2b, the 282 genes differentially expressed due to
diabetes are grouped according to their function [for a
complete list, see Additional file 1]. The analysis of the
arrays from DT animals identified 88 differentially
expressed genes (see Figure 2c for functional clustering,
and Additional file 2 for the complete list). The majority
of these genes (70%) represented genes whose expression
was restored, in varying degrees, by the tungstate treat-
ment. Among these genes are the ones involved in metab-
olism, protein modification, oxidative stress, and so on,
showing that the treatment acts on several pathways
which lead to the recovery of pancreatic function. Only 28
of the 88 genes were differentially expressed in DT ani-
mals alone [see Additional file 3].
Validation of the array results
After an exhaustive bibliographical research, from the list
of all the genes modified by tungstate in the diabetic ani-
mals we chose a selection of genes whose function would
help us to explain the effects observed in the pancreas of
the tungstate-treated diabetic animals (further informa-
tion available in Additional file 4 and Discussion), and we
rechecked their expression using quantitative PCR. The
genes chosen were transforming growth factor beta 3
(Tgfb3), fibroblast growth factor 13 (Fgf13), X-box bind-
ing protein 1 (Xbp1), uterine sensitization-associated
gene-1 (Usag-1), tetraspanin 8 (Tspn8), suppressor of lin-
12 1 homolog (Sel1h), and Raf kinase inhibitory protein
(Rkip). The analysis is shown in Figure 3a. The results were
similar to those found in the microarray analysis. Interest-
ingly, gene expression was lower in DU than in HU ani-
mals (except Tspn8, which was unchanged, and Rkip,
which was increased), whereas in DT animals, gene
expression increased significantly as compared to DU, and
sometimes it even surpassed HU. Insulin 2 and amylase
were also included as controls. As in the microarrays and
in the biochemical data, the expression of these genes was
extremely low (almost zero) in the DU rats, and tungstate
treatment partially restored amylase expression (a 45.98 ±
10.97 fold increase DT vs. DU, p < 0.01) and increased
insulin expression (a 4.49 ± 1.10 fold increase DT vs. DU,
p < 0.001).
Tungstate effects are independent of glycemia 
normalization
Hyperglycemia has a critical impact on beta cell function
[14] and gene expression [15]. To assess the involvement
of the decrease in the hyperglycemia on tungstate effects,
we decided to explore whether the gene expression
changes induced by the treatment were just the conse-
quence of the decrease in glycemia observed in the dia-
betic treated animals. To do so, diabetic rats were treated
with phloridzin, which selectively inhibits active glucose
reabsorption in the kidneys and, as opposed to insulin
administration, leads to a decrease in glycema without
any direct effect on pancreas function. Phloridzin admin-
istration led to a significant decrease in glycemia, though
healthy values were not attained; interestingly, the levels
reached were quite similar to those observed in DT ani-
mals (Figures 3b and 1a). Analysis of the expression of the
genes validated by Real Time PCR showed that most did
not present significant differences between the phloridzin
administrated animals and their control counterparts
(Figure 3c). Nevertheless, Sel1h and insulin expression
increased significantly (insulin: 1.82 ± 0.32 fold increase,
Sel1h: 1.45 ± 0.18 fold increase, p < 0.05 vs. untreated ani-
mals), although this increase was lower than the one
observed in the tungstate-treated diabetic rats (insulin:
4.49 ± 1.10 fold increase, Sel1h: 4.21 ± 0.31, p < 0.001 vs.
DU). Nuclear protein 1 (Nupr1), which has been shown
to be regulated by glucose levels [16], was included as a
positive control, and, as expected, it was significantly
reduced in phloridzin-treated animals. Therefore, we con-
clude that tungstate effects on gene expression are inde-
pendent of the decrease in glycemia.
Tungstate increases beta cell proliferation indirectly 
through the modification of the serum profile
Tungstate administration to the diabetic animals
increased beta cell proliferation. This increase was respon-
sible, at least partially, for the beta cell mass recovery
observed in the diabetic animals. Firstly, we assessed
whether tungstate alone in culture was able to increase
beta cell proliferation. As shown in Figure 4a, in culture,
tungstate slightly increased INS-1E proliferation. How-
ever, this increase was much lower than the one observed
in vivo; therefore, we wondered whether tungstate admin-
istered in vivo was able to exert a greater effect due either
to the action of one of its metabolites or due to some indi-
rect mechanisms. To shed some light on the matter, we
cultured INS-1E cells in the presence of serum from the
treated animals. Surprisingly, the sera from the diabetic
treated rats were able to enhance INS-1E proliferation
(Figure 4b). This increase was greater than the one
observed when the cells were treated with tungstate
directly. Moreover, when tungstate was added to a
medium containing foetal bovine serum, no differences
were observed (data not shown), suggesting that tungstate
was not acting through the enhancement of some trophic
factors present in the serum. In conclusion, tungstate acts
on beta cell proliferation in diabetic animals probably
through an indirect mechanism.Page 5 of 13
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Tungstate effects on the genes identified using the microarrays are specific and independent of glycemia normalizationFigure 3
Tungstate effects on the genes identified using the microarrays are specific and independent of glycemia nor-
malization. a From the list of specific genes modified in the diabetic treated animals, a significant number were chosen to cor-
roborate the difference in expression levels detected by microarray analysis, using Real Time PCR, n = 7. ***p < 0.001, **p < 
0.01 and *p < 0.05 compared to healthy untreated animals, †††p < 0.001, ††p < 0.01 and †p < 0.05 compared to diabetic 
untreated animals. b Diabetic animals were treated with phloridzin to decrease glycemia. Blood glucose levels during phloridzin 
administration, n = 12. ***p < 0.001 compared to vehicle treated animals. c mRNA expression levels from the pancreas of 
phloridzin treated animals were analyzed by Real Time PCR, n = 10. *p < 0.05 compared to vehicle treated animals.
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Effects of tungstate and serum from tungstate treated animals on beta cell proliferation and analysis of p42/44 phosphorylation capacityFigure 4
Effects of tungstate and serum from tungstate treated animals on beta cell proliferation and analysis of p42/44 
phosphorylation capacity. a Tungstate induction of INS-1E cells proliferation. INS-1E cells were cultured with or without 
tungstate (100 μM) in the absence of fetal bovine serum. n = 5, *p < 0.05 vs. control. b Serum from diabetic treated animals 
enhances INS-1E proliferation. The cells were cultured in RPMI media containing 10% of the serum from the animals of each 
experimental group (HU, DU and DT). Serum samples were obtained after 5 weeks treatment with tungstate. n = 5. *p < 0.05 
vs. healthy untreated animals and †p < 0.05 compared to diabetic untreated animals. c-f INS-1E cells were treated (c and e) 
with tungstate, or with serum from the untreated and treated diabetic animals (d and f) for the minutes indicated. Lysates were 
immunoblotted (representative Western blots are shown, c-d), quantified (e-f) and expressed as the logarithmic fold change of 
phosphorylated p42/44 protein normalized by the total quantity of p42/44 for each time point vs. time 0 (n = 4–5). **p < 0.01 
and *p < 0.05 vs. time 0 and †p < 0.05 as compared to the same point time in the samples treated with serum from the diabetic 
untreated animals.
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proliferation
Among several other cellular functions, the MAPK path-
way plays a key role in cell replication [17]. One of the
tungstate-specific genes that we have analyzed is Rkip,
which is involved in the fine tuning of this important
pathway in the islets through the inhibition of Raf-1 [18].
This gene was increased in the diabetic untreated animals
compared to untreated healthy rats (inhibiting the MAPK
p42/44 pathway), and the treatment returned its levels to
normal (re-establishing MAPK p42/44 signalling) (Figure
3a). Moreover, previous studies [10] have demonstrated
that sodium tungstate is able to activate the MAPKp42/44
pathway by increasing p42/44 phosphorylation in hepa-
tocytes. Therefore, we decided to further evaluate the role
of the MAPK pathway in tungstate-induced beta cell repli-
cation. We observed that tungstate was able to stimulate
the MAPK pathway in INS-1E (Figure 4c and 4e). Simi-
larly, the serum from the diabetic treated animals was also
able to enhance the MAPK pathway more strongly than
the serum from the untreated animals (notice the differ-
ent scales used in Figures 4e and 4f); in addition, the acti-
vation of the pathway lasted longer (Figures 4d and 4f).
This MAPKp42/44 activation pattern mimics the findings
observed with the INS-1E proliferation in the presence of
tungstate and serum from the different animals, showing
also that serum from diabetic treated animals is a more
potent proliferative agent and activator of the MAPK p42/
44 pathway. Since it seemed that the stimulation of beta
cell replication was linked to MAPK activation, we
decided to culture INS-1E cells with PD98059, a MAPK/
ERK kinase 1 (Mek1) inhibitor [19]. In the presence of
PD98059, the serum from the treated animals induced a
lower stimulation of beta cell replication (62% reduction,
p < 0.05, n = 6), but no significant effect was seen in the
serum from the untreated animals (8% reduction, p = n.s.,
n = 6). These data suggest that in order to exert its effects
on beta cell replication, tungstate has to activate the
MAPK pathway by both short-term (direct activation) and
long-term mechanisms (normalization of Rkip expres-
sion), probably through an indirect mechanism involving
either tungstate metabolization or the stimulation of
some beta cell trophic factor(s).
Discussion
This paper focuses on the molecular mechanisms by
which tungstate administration modulates pancreatic
plasticity in diabetic animals. We selected the streptozo-
tocin rat model, which shows a high degree of pancreatic
damage at both endocrine and exocrine levels [20]. In this
situation, tungstate administration partially restores glyc-
emia, insulinemia and amylasemia. Moreover, the mor-
phological results clearly demonstrate that treatment
increased beta cell mass in the pancreas and increased
insulin and Pdx-1 positive cells in the islets. This increased
beta cell mass can be ascribed, at least in part, to a combi-
nation of a decrease in beta cell apoptosis and an increase
in islet proliferation.
In agreement with the metabolic phenotype, the pancre-
atic microarray analysis found no differences in the gene
expression pattern between HU and HT animals, but it
showed a very different pattern in DU animals as com-
pared with both healthy samples. These changes are
found not only in genes linked to endocrine function but
also in those linked to exocrine function, probably due to
the toxic effects of STZ. Finally, DT animals presented a
specific pattern which was different from both DU ani-
mals and healthy animals, due to the effects of sodium
tungstate on the diabetes background.
The analysis of the microarray data led us to propose a
model of tungstate action (Figure 5) which could explain
the general improvement in the exocrine and endocrine
pancreatic function of the diabetic animals treated with
sodium tungstate. To understand these effects, we should
bear in mind that tungstate is able to inhibit phosphatase
activity due to its chemical properties [21]. Our group and
others have shown that, probably as a result of this prop-
erty, tungstate treatment increases the phosphorylation of
key proteins of different pathways [9,10] and is probably
responsible for the effects of tungstate in diabetic animals.
Thus, the combination of these two actions – modifica-
tion of gene expression and enhancement of phosphor-
ylation – may cooperate synergistically to increase beta
cell mass, which, together with the improvement of
hepatic metabolism [5], would lead to a decrease in
hyperglycemia.
In relation to the recovery of exocrine function, we should
mention the possible role of Xbp1. This gene plays a key
role in the unfolded protein response [22], and Xbp1
knockout animals display abnormalities exclusively in
secretory organs such as the exocrine pancreas, which lead
to early postnatal lethality [23]. In our model, we found
Xbp1 to be decreased in the DU animals and increased in
the DT animals concomitantly to the recovery of the amy-
lase expression, a finding that stresses the important role
of this gene in the correct function of the exocrine
machinery.
Several genes whose expression was modified by tungstate
administration to diabetic animals may be responsible for
the recovery of pancreatic function. Those genes are
involved in different pathways which control a wide range
of physiological functions, covering growth and differen-
tiation to morphogenesis and angiogenesis. Therefore, it
is probably the combination of tungstate effects upon all
these pathways that leads to the recovery of pancreatic
function. Since we performed microarrays using the total
pancreas, we cannot identify the exact sites of these
changes (exocrine, endocrine or ducts). Nevertheless, itPage 8 of 13
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creatic regeneration observed in the diabetic treated ani-
mals. Fgf13 is one of the genes modified in the diabetic
treated animals. Fgf13 binds to islet-brain 2, recruiting
p38δ and increasing the activity of this kinase [24]. Inter-
estingly, it has already been shown that tungstate
increases the phosphorylation of p38 in both MIN6 beta
cells [25] and islets of nSTZ-rats [9], which may lead to the
improvement observed in the pancreatic beta cell popula-
tion. Another modified gene was Tspn8, which may exert
tumor-promoting activities by increasing cell motility and
by inducing angiogenesis [26]. Therefore, bearing in mind
that STZ damage provokes severe microcirculatory distur-
bances within pancreatic islets [27], we propose that an
increase in the Tspn8 expression may improve pancreas
revascularization and enhance islet function. Finally,
other interesting genes are Tgfb3, Usag-1 and Sel1h. Tgfb3
plays a key role in complex processes including epithelial
to mesenchymal transition [28], which is relatively impor-
tant in pancreas regeneration [29,30]. Usag-1 modulates
Wnt and Bone Morphogenic Protein signaling [31-33] in
different ways. Sel1h has been implicated as a Notch
inhibitor in exocrine [34] and endocrine replication [35]
and modifies the expression of genes involved in cell-
matrix interactions and in the cell cycle [36]. Although the
exact role of these genes in pancreatic regeneration has not
been investigated in detail, we hypothesize that the com-
bined action of these multiple pathways leads to the
regeneration of the pancreas observed in the DT rats.
Although many pathways are involved in tungstate action,
the results clearly show that the MAPK pathway plays a
key role. The array analysis showed normalization in Rkip
expression in the DT animals. This protein binds to v-raf-
1 murine leukemia viral oncogene homolog 1 (Raf-1),
leading to the blockage of Mek and extracellular-signal-
regulated kinase 1 (Erk) activation. It has been shown
that, in the pancreas, Rkip localizes specifically in the
islets and is involved in the regulation of beta cell growth.
When this gene is up-regulated, as in the case of the DU
animals, it acts as a brake on the MAPK signaling and beta
cell proliferation [18]. The normalization of Rkip in the
DT rats would permit the unblocking of the MAPK signal-
ing and thus allowing the proliferative signals through
this pathway. In the liver, it has been shown that tungstate
enhances glycogen synthesis through MAPK activation
Pathways involved in the effects of tungstate on the pancreasFigure 5
Pathways involved in the effects of tungstate on the pancreas. Microarrays from diabetic treated animals show that 
tungstate is acting through many interconnected pathways, which lead to an overall improvement of pancreas function. Some 
of the genes found are over-expressed (red) or diminished (blue) in diabetic treated animals and are involved in the control of 
several cellular pathways, either activating (arrows) or repressing (lines with a perpendicular line at the end). The final effects of 
the activation or inhibition of these pathways are described at the bottom of the figure. Moreover, the phosphorylations are 
represented as circles with a P inside, and the tungstate effects described for enhancing the phosphorylation of different key 
proteins are shown with a black star [9,10,25].Page 9 of 13
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both directly and indirectly and is crucial for the tung-
state-induced increase observed in beta cell replication.
On the one hand, tungstate enhances MAPK phosphoryla-
tion; on the other, it normalizes Rkip expression which
also leads to an increase in the MAPK pathway tone. The
combination of these two mechanisms is the cause of the
increased beta cell proliferation observed in our study.
Conclusion
In summary, tungstate is able to increase beta cell mass
and recovers the exocrine and partially endocrine function
in STZ-rats. These improvements in pancreatic function
require the combined action of several pathways, such as
Wnt, TGF-b, Notch and MAPK. The last of these is clearly
involved in the increase in beta cell mass. This study iden-
tifies several proteins that may play a key role in the
improvement of pancreatic plasticity. Further studies will
help us to identify their precise role in the pancreas.
Methods
Animals, induction of diabetes and tungstate treatment
Principles of laboratory animal care were followed (Euro-
pean and local government guidelines) and protocols
were approved by the Animal Research Committee of the
University of Barcelona. Diabetes induction and tungstate
treatment have been described previously [8]. Diabetes
was induced in adult male Wistar rats (225 g) obtained
from Charles River (Wilmington, MA, USA) by an intra-
peritoneal STZ (Sigma, St Louis, MO, USA) injection (70
mg/Kg). At the beginning of the experiment, both diabetic
and healthy animals were randomly divided into two
groups. For 5 weeks, treated rats received ad libitum a solu-
tion of 2 mg/ml sodium tungstate (Carlo Erba, Rodano,
Italy) in deionized water; whereas the untreated rats
received deionized water alone (daily sodium tungstate
intake: healthy 71 mg, diabetic 110 mg). Therefore, the
study had 4 experimental groups (healthy untreated
[HU], healthy treated [HT], diabetic untreated [DU] and
diabetic treated [DT]). Glycemia was measured every 5
days. At the end of the experiment, blood was collected,
and serum was obtained. For islet studies, islets were iso-
lated by collagenase digestion, as previously described [9].
Phloridzin administration
In an additional group of animals, diabetes was induced
by STZ injection, as described in the previous section.
Once the hyperglycemia was confirmed, these diabetic
animals were subdivided into two groups, one group
(control) which received the vehicle used to dissolve
phloridzin; and the other group (treated) which received
phloridzin as previously described [37]: phloridzin
(Sigma) was dissolved (40%) in propylene glycol (Sigma)
and injected intraperitoneally every 8 h during 1 week at
a dose of 2 g/Kg body weight per day. Phloridzin treated
rats also underwent a caloric restriction of 0.1 g chow diet/
Kg body weight per day.
Insulinemia and amylasemia
Insulinemia was measured by radioimmunoassay (CIS,
Gif-sur-Yvette, France), and amylasemia was determined
in an Advia Analyzer 2400 (Siemens Medical Solutions
Diagnostics, Munich, Germany)
Immunohistochemical studies and beta cell analysis
The whole pancreas was removed, fixed and embedded in
paraffin. Serial sections of pancreas (5 μm) were obtained
from three different levels. Beta cells were located using a
modified avidin-biotin-peroxidase method [38]. The
morphometric analysis was performed using OPTIMAS™
(Bioscan Incorporated, Edmonds, WA, USA) software. We
also stained for pancreatic duodenal homeobox-1 (Pdx-1)
(kindly provided by Dr. C. Wright), quantifying the per-
centage of Pdx-1-labeled cells within the islet cells (not
less than 1000 cells were counted).
Cell replication rates
Sequential-dual staining for proliferating cell nuclear anti-
gen (PCNA) (Sigma) and insulin (Dako, Glostrup, Den-
mark) was performed. Replication rate was quantified and
expressed as the percentage of PCNA-labeled cells among
the total beta cells counted (not less than 3000 each).
Immunohistochemical stainings have been validated in
previous studies [39,40].
Apoptotic rate
To identify apoptotic bodies, we used the propidium
iodide technique [1]. Deparaffinized and rehydrated sec-
tions were incubated for 30 minutes in a solution of pro-
pidium iodide (4 μg/ml, Sigma) and RNAse A (100 μg/ml,
Sigma). For the quantitative evaluation, positively labeled
apoptotic endocrine cells were counted, and the number
of apoptotic cells was expressed as the percentage of the
total number of beta cells counted.
RNA isolation
RNA was isolated from fresh total pancreas using the
RNAgents Total RNA Isolation System (Promega, Madi-
son, WI, USA). Islet RNA was isolated with the RNeasy
Mini Kit (Qiagen, Venlo, The Netherlands). RNA integrity
was analyzed using a Lab-on-a-chip in a 2100 Bioanalyzer
(Agilent Technologies, Santa Clara, CA, USA).
Microarrays
Total RNA from 3 rat pancreases of the same experimental
group was pooled in equal proportions and hybridized to
a Rat GeneChip RAE230-A (Affymetrix, Santa Clara, CA,
USA). In total, 12 microarrays were hybridized using 3 dif-
ferent pools of each experimental group. The data were
deposited in NCBIs Gene Expression Omnibus with the
accession number GDS1883. Several quality controls werePage 10 of 13
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file 5, 6, 7 and 8], and analyzed, as described in Additional
file 9, using Affy [42,43], AffyPLM [44] and LIMMA [45]
packages from Bioconductor [46] on R language [47,48]
and dChip software [49].
Values for clustering were obtained after standardizing the
gene values: the mean value of each gene was subtracted
from the value of this gene in each array and was divided
by the standard deviation of this gene in all the arrays.
Clustering was performed with a distance metric of 1 –
correlation, centroid linkage method and gene ordering
by cluster tightness
Real Time PCR
Total RNA was retrotranscripted with SuperscriptIII (Inv-
itrogen, Carlsbad, CA, USA). Real Time PCR was carried
out in a 7900 HT Real Time System (Applied Biosystems,
Foster City, CA, USA) using SYBR Green fluorophor. The
primers used are described in Additional file 10. A stand-
ard curve of each primer set was generated from serial
dilutions of cDNA. The PCR products were verified by way
of dissociation curve analysis using SDS software (Applied
Biosystems). Expression levels obtained were normalized
with a housekeeping gene (TATA box binding protein)
and were scaled to the mean of the values of the same gene
found in the healthy untreated animal.
Western Blot
Western blotting was performed as described previously
[9], using a specific antibody against phospho-p42-p44
MAPK (Thr202/Tyr204; Cell signaling, Danvers, MA,
USA). Membranes were then stripped and incubated with
anti-p42-p44 MAPK (Cell signaling). Intensity values
were obtained with Image Gauge 4.0 software (Fujifilm,
Valhalla, NY, USA). These values were divided by the
value obtained at time 0, in order to normalize the data
and permit comparisons among experiments performed
on different days. Finally, data was log 2 transformed in
order to obtain additive normally distributed noise and to
stabilize variance [50].
Cell proliferation
INS-1E cells (kindly provided by Dr P. Maechler) were
maintained as described elsewhere [51]. For serum prolif-
eration studies, two days after seeding, the medium was
substituted by a medium containing RPMI1640 (Biosera,
Ringmer, UK), BSA 0.1%, glucose 5 mmol/l and sodium
tungstate at 100 μmol/l (Carlo Erba) or 10% of the serum
from the animals. 24 hours later, hydroxyurea 12.5
mmol/l (Sigma) was added to the medium. 24 hours
later, the medium was removed, and wells were cleaned
with DPBS (Sigma). A medium with the initial composi-
tion supplemented with methyl-3H-Thymidine 1 μCi
(initial specific activity 74 GBq/mmol) (GE Healthcare,
Fairfield, CT, USA) was added to each well for 4 hours.
Plates were then frozen and defrosted, cells were harvested
with a Cell Harvester, and cpm was measured with a 1205
BetaPlate liquid scintillation counter (Perkin Elmer,
Waltham, MA, USA).
Phosphorylation studies
Two days after seeding INS-1E cells, in order to decrease
basal phosphorylation levels, the medium was substituted
by RPMI1640 without any supplement. Eight hours later,
the medium was substituted by RPMI1640 comple-
mented with 10% of the serum from animals of the differ-
ent experimental groups or sodium tungstate (100 μmol/
l). After 0, 5, 15, 30 and 60 minutes, the plates were rinsed
with DPBS and frozen.
Statistical analysis
Quantitative data are expressed as means ± SEM. The sta-
tistical significance was determined by Student's t-test
(when only two groups were analyzed: glycaemia of the
phloridizin treated animals, Real-time PCR values of the
phloridizin treated animals and tungstate treated cells
replication) and ANOVA (when more than two groups
were analyzed: the rest), with a Tukey's Post-Hoc test used
to find the groups responsible for the statistical signifi-
cance.
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